Endometrial Cancer Clinical Trials in Fairfax, Virginia

29 studies are recruiting for endometrial cancer in Fairfax, Virginia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

   This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Virginia, Fairfax, Virginia

   Locations

   6 in total

   Run by

   Regor Pharmaceuticals Inc.

   See if you can join NCT07524322 on ClinicalTrials.gov

2. CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

   The purpose of this study is to determine the safety and tolerability of monotherapy CR-002 and to identify the MTD and/or optimal biologic dose and RP2D(s) in participants with locally advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Clinical Study Site, Fairfax, Virginia

   Locations

   3 in total

   Run by

   Crescent Biopharma, Inc.

   See if you can join NCT07909031 on ClinicalTrials.gov

3. Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

   This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Virginia Cancer Specialists, Fairfax, Virginia

   Locations

   11 in total

   Run by

   Sairopa B.V.

   See if you can join NCT05856981 on ClinicalTrials.gov

4. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

   This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, Fairfax, Virginia

   Locations

   25 in total

   Run by

   Terremoto Biosciences Inc.

   See if you can join NCT07109726 on ClinicalTrials.gov

5. Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

   This study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts: * Part 1A is a dose escalation of STRO-006 monotherapy in selected tumor types reported to commonly express ITGB6. Part 1A will determine the safety, tolerability, pharmacokinetics (PK), and preliminar…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology Virginia, Fairfax, Virginia

   Locations

   6 in total

   Run by

   Sutro Biopharma, Inc.

   See if you can join NCT07807345 on ClinicalTrials.gov

6. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

   This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Virginia Cancer Specialists, Fairfax, Virginia

   Locations

   88 in total

   Run by

   Artios Pharma Ltd

   See if you can join NCT04657068 on ClinicalTrials.gov

7. A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

   This is a Phase 1, two-part, open-label, nonrandomized, dose-escalation and signal-seeking study of CGT6297, evaluating the safety, tolerability, PK, pharmacodynamic (what the drug does to the body), and antitumor activity of CGT6297 in adult participants with advanced solid tumors harboring PIK3CA…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Virginia, Fairfax, Virginia

   Locations

   12 in total

   Run by

   Cogent Biosciences, Inc.

   See if you can join NCT07383506 on ClinicalTrials.gov

8. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

   The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Virginia Cancer Specialists, Fairfax, Virginia

   Locations

   26 in total

   Run by

   SystImmune Inc.

   See if you can join NCT06293898 on ClinicalTrials.gov

9. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

   Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicates that certain normal proteins are present in the cancer cel…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Inova Schar Cancer Institute ( Site 6003), Fairfax, Virginia

   Locations

   268 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06952504 on ClinicalTrials.gov

10. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participant…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Research Site, Fairfax, Virginia

    Locations

    257 in total

    Run by

    AstraZeneca

    See if you can join NCT06989112 on ClinicalTrials.gov

11. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    USOR Virginia Cancer Specialists, Fairfax, Virginia

    Locations

    66 in total

    Run by

    Genmab

    See if you can join NCT05579366 on ClinicalTrials.gov

12. Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

    This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors

    Stage

    Phase 1

    Ages

    18 to 130

    Site

    Research Site, Fairfax, Virginia

    Locations

    60 in total

    Run by

    AstraZeneca

    See if you can join NCT05797168 on ClinicalTrials.gov

13. A Study of PHST001 in Advanced Solid Tumors

    This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advan…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology - Virginia, Fairfax, Virginia

    Locations

    20 in total

    Run by

    Pheast Therapeutics

    See if you can join NCT06840886 on ClinicalTrials.gov

14. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Virginia Cancer Specialists, Fairfax, Virginia

    Locations

    76 in total

    Run by

    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

15. A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

    A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects with Select Advanced Solid Tumors. The main goals of this study are to: * Find the recommended dose of TS-104 that can safely be given to p…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Site 04, Fairfax, Virginia

    Locations

    3 in total

    Run by

    TwoStep Therapeutics, Inc.

    See if you can join NCT07814248 on ClinicalTrials.gov

16. Study of AVZO-021 in Patients With Advanced Solid Tumors

    This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Avenzo Therapeutics Recruiting Site, Fairfax, Virginia

    Locations

    13 in total

    Run by

    Avenzo Therapeutics, Inc.

    See if you can join NCT05867251 on ClinicalTrials.gov

17. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Virginia Cancer Specialists, Fairfax, Virginia

    Locations

    37 in total

    Run by

    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

18. Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

    This is a Phase 1 study to assess safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ARR-002 in advanced or metastatic ovarian or endometrial cancer.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, Fairfax, Virginia

    Locations

    6 in total

    Run by

    ArriVent BioPharma, Inc.

    See if you can join NCT07755436 on ClinicalTrials.gov

19. A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

    This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a coh…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Virginia, Fairfax, Virginia

    Locations

    9 in total

    Run by

    Sutro Biopharma, Inc.

    See if you can join NCT07227168 on ClinicalTrials.gov

20. A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

    This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Normunity Investigational Site, Fairfax, Virginia

    Locations

    18 in total

    Run by

    Normunity AccelCo, Inc.

    See if you can join NCT07182149 on ClinicalTrials.gov

21. Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

    HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology - Virginia Cancer Specialists, Fairfax, Virginia

    Locations

    12 in total

    Run by

    Whitehawk Therapeutics, Inc.

    See if you can join NCT07444814 on ClinicalTrials.gov

22. Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

    This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following pla…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Research Site, Fairfax, Virginia

    Locations

    320 in total

    Run by

    AstraZeneca

    See if you can join NCT07044336 on ClinicalTrials.gov

23. A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

    This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tum…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Virginia, Fairfax, Virginia

    Locations

    62 in total

    Run by

    Seagen, a wholly owned subsidiary of Pfizer

    See if you can join NCT05208762 on ClinicalTrials.gov

24. Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

    This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    522, Fairfax, Virginia

    Locations

    49 in total

    Run by

    Corcept Therapeutics

    See if you can join NCT06906341 on ClinicalTrials.gov

25. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

    A Study of Emi-Le in Participants with Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology Virginia, Fairfax, Virginia

    Locations

    26 in total

    Run by

    Day One Biopharmaceuticals, Inc.

    See if you can join NCT05377996 on ClinicalTrials.gov